



As this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, Applicants estimate that no fee is required. Should a fee be required, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,


*Anthony M. Insogna, Reg. No. 35,203*  
*By: Michael J. Bruner, Reg. No. 47,458*

Date November 11, 2004

By: Michael J. Bruner (Reg. No. 47,458)

For: Anthony M. Insogna (Reg. No. 35,203)

**JONES DAY**  
222 East 41st Street  
New York, New York 10017  
(858) 314-1130



Delivered by Hand  
Sheet 1 of 2

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.  
9516-070-999  
(Cam No. 501872-999069)

APPLICATION NO  
10/749,344

APPLICANT  
Jerome B. Zeldis

FILING DATE  
December 30<sup>th</sup>, 2003

GROUP  
1632

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	3,095,415	6/25/63				
	A02	3,522,263	7/28/70				
	A03	3,541,110	11/17/70				
	A04	4,879,252	11/07/89				
	A05	5,985,867	11/16/99				
	A06	6,114,333	9/05/00				
	A07	6,361,760	11/26/02				
	A08	6,555,539	4/29/03				
	A09	US 2002/0161022	10/31/02				

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/	B01	CS 146 895 1	11/12/71					
/	B02	DE 1266763	4/25/68					
/	B03	GB 1293557	9/04/70					
/	B04	GB 1404969	8/24/73					
/	B05	GB 1576217	7/22/77					
/	B06	GB 2003477	3/30/79					
/	B07	GB 1489280	10/19/77					
/	B08	GB 2345486	7/12/00					
/	B09	WO 01/12609	2/22/01					
/	B10	WO 02/10137	2/7/02					
/	B11	WO 02/46170	6/13/02					
/	B12	WO 89/10924	11/16/89					

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

/	C01	Adam, J. et al., "Coagulation and Fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms" Vascular Surgery, v. 30(4), pp. 641-650 (1999)
/	C02	Ames et al., "An integrated concept of amebicidal action: electron transfer and oxy radicals", Free Radical Biol. Med. 3:85-96 (1987)
/	C03	Andronati, Dopov. Akad. Nauk. Ukr., v. 8, pp. 126-131 (1994)
/	C04	Arya et al., "Synthesis of Nitroheterocycles: Part IV*-Synthesis of I-Substituted 4-Nitroisoquinolines, 5- & 6-Nitroindazoles & 6-Nitrobenzimidazoles" Indian J. Chem., Sect. B, v. 15B(7), pp. 625-628 (1977)
/	C05	Boehm et al., "Novel Inhibitors of DNA Gyrase: 3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random Screening" J. Med. Chem., v. 43(14), pp. 2664-2674 (2000)
/	C06	Buck, K., "Total Synthesis of Peruvianine, A Phenolic 7-oxoaporphine alkaliod of Telitoxicum Peruvianum" Heterocycles, v. 36(11), pp. 2489-2495 (1993)

C07	Espinola-Klein C. et al., "Manifestationen der Atherosklerose in verschiedenen Gefäßregionen" Med. Klin. 97(4):221-228, (2002)
C08	Fujimura et al., "Synthesis and Pharmacological Activities of 2,3-Dihydro-1-H-pyrazolo-[1,2-a]indazolium Derivatives" v. 106(11), pp. 1002-1007 (1986)
C09	Galushko and Dokunikhin, "Pyrazoloanthrone derivatives I. Reactivity of 3-aminopyrazoloanthrone", Khimiya Geterotsiklicheskikh Soedinenii, 7:956-961 (1977)
C10	Gupta et al., "Selective interaction of JNK protein kinase isoforms with transcription factors" EMBO J. 15:2760-2770, (1996)
C11	Gvon et al., "Amino-imino tautomerism and intramolecular cyclization of 4, 9-diamino-1, 10-anthraquinone-1-tosylimines" Dokl. Akad. Nauk, 334:465-468 (in Russian with English abstract) (1994)
C12	Hartley et al., "Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids: structural requirements for DNA binding, intercalation, and photosensitization", Mol. Pharmacol. 33:265-271 (1988)
C13	Hibi et al., "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain", Genes Dev. 7:2135-2148 (1993)
C14	Ishizuka et al., "Mast cell tumor necrosis factor $\alpha$ production is regulated by MEK kinases", Proc. Natl. Acad. Sci. USA 94:6358-6363 (1997)
C15	Ivanova et al., "XPS investigation of electronic structure of pyrazoloanthrone and its derivatives" Poverkhnost, 4-5:193-201 (1997)
C16	Jones, W., "The Reaction of 4-Alkyl-3-thiosemicarbazides with $\beta$ -Haloketones" Heterocycl. Chem., v. 20(5), pp. 1359-1361 (1983)
C17	Judson, "The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer", Semin. Oncol. 19:687-694 (1992)
C18	Kawakami et al., "NaH-Mediated One-Pot Cyclocondensation of 6-Nitroquinoline with Aromatic Hydrazone to Form [1,2,4]Triazino[6,5-f]quinolines and/or Pyrazolo[3,4-f]quinolines" Organic Letters, v. 2(3), pp. 413-415 (2000)
C19	Mohit et al., "p49 <sup>3F12</sup> kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system", Neuron 14:67-78 (1995)
C20	Patel et al., "Unsymmetrical cyclic ureas as HIV-1 Protease Inhibitors: Novel Biaryl Indazoles as P2/P2' Substituents" Bioorganic and Medicinal Chemistry Letters, v. 9(22), pp. 3217-3220 (1999)
C21	Pfoertner and Foricher "1 H-Indazoles Obtained by Photolysis of 2-Aminophenylketon-O-(ethoxycarbonyl) oximes and of 3,1,4-Benzoxadiazephen-2(1 H)-ones", Helv. Chim. Acta, v. 65(3), pp. 798-806 (1982)
C22	Ross, R., "Cell Biology of Atherosclerosis" Annu. Rev. Physiol. 57:791-804, (1995)
C23	Showalter et al., "Design, Tumor Biology, and Biochemical Pharmacology of Anthrapyrazoles" Bioact. Mol. Chapter V1:201-243 (1988)
C24	Showalter et al., "5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation", J. Med. Chem. 27:253-255 (1984)
C25	Showalter et al., "Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias", J. Med. Chem. 30:121-131 (1987)
C26	Singh and Shah, "Reactions of 2,2'-ethylene-bis-anthrapyrazolone", Indian J. -Chem. 16B:100-102 (1978)
C27	Sokolyuk et al., "Synthesis and photochemical properties of peri-phenoxy derivatives of 6H-anthra[1,9-cd]-6-pyrazolone (pyrazoloanthrone)", Zhurnal Organicheskoi Khimii 28:2193-2200 (1992)
C28	Swantek et al., "Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF- $\alpha$ ) translation: glucocorticoids inhibit TNF- $\alpha$ translation by blocking JNK/SAPK", Mol. Cell. Biol. 17:6274-6282 (1997)
C29	Takano et al., "High levels of Circulating Macrophage Colony Stimulating Factor (M-CSF) Predict Restenosis after Primary Angioplasty in Patients with Acute Myocardial Infarction" Circulation, 98 (17, Supp):4437 (1998)
C30	Tardif et al., "Probulcol and Multivitamins in the Prevention of Restenosis after Coronary Angioplasty" N. Engl. J. Med.: 337(6):365-72 (1997)
C31	Vasilevsky et al., "Cyclocondensation of activated ortho-chloroarylacetylenes with hydrazine: a novel route to substituted indazoles" Mendeleev. Commun., v. 3, pp. 98-99 (1996)
C32	Walser, J. Heterocycl. Chem., v. 11(6), pp. 885-888 (1974)
C33	Wrzeciono et al., "Part 14: On the behaviour of 5-Chloro-2-Nitroindazole Against Aliphatic and Cyclic Amines" Pharmazie, v. 40(2), pp. 105-108 (1985)
C34	Wrzeciono et al., "Part 33: 5-Fluoroindazole derivatives" Pharmazie, v. 47(1), pp. 22-24 (1992)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.